Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review

Immune-mediated adverse events (imAEs) are complications of therapy with immune checkpoint inhibitors, which arise as a result of autoimmune inflammation. The article summarizes systemic (fatigue, fever), cutaneous (rash, itching), gastrointestinal (diarrhea, colitis, hepatitis, pancreatic dysfuncti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marina A. Lyadova, Vladimir K. Lyadov
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	immune-mediated adverse events immune checkpoint inhibitors toxicity Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3a154e511d494ed0b9aa3f44adddd121
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3a154e511d494ed0b9aa3f44adddd121
record_format	dspace
spelling	oai:doaj.org-article:3a154e511d494ed0b9aa3f44adddd1212021-11-30T16:55:01ZImmune-mediated adverse events in immune checkpoint inhibitors therapy: literature review1815-14341815-144210.26442/18151434.2021.2.200502https://doaj.org/article/3a154e511d494ed0b9aa3f44adddd1212021-08-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/77938/58525https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Immune-mediated adverse events (imAEs) are complications of therapy with immune checkpoint inhibitors, which arise as a result of autoimmune inflammation. The article summarizes systemic (fatigue, fever), cutaneous (rash, itching), gastrointestinal (diarrhea, colitis, hepatitis, pancreatic dysfunction), endocrinological (hypothyroidism, hypophysitis, adrenal insufficiency, diabetes mellitus), pulmonary (pneumonitis, pleuritis), rheumatological (arthralgia), neurological (headache, sensory and motor disorders), renal (acute interstitial nephritis, lupus-like nephritis, granulomatous nephritis, diffuse interstitial nephritis and minimal change disease), hematological (anemia, cytopenia), cardiovascular (myocarditis) and ocular (conjunctivitis, episcleritis, ceratitis, blepharitis and uveitis) imAE. Pathogenetic mechanisms and treatment approaches (in accordance with toxicity grade and clinical recommendations) are discussed. Early symptom recognition, patient education and timely intervention are crucial for imAE correction.Marina A. LyadovaVladimir K. LyadovIP Habib O.N.articleimmune-mediated adverse eventsimmune checkpoint inhibitorstoxicityNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 2, Pp 319-326 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	immune-mediated adverse events immune checkpoint inhibitors toxicity Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	immune-mediated adverse events immune checkpoint inhibitors toxicity Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Marina A. Lyadova Vladimir K. Lyadov Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
description	Immune-mediated adverse events (imAEs) are complications of therapy with immune checkpoint inhibitors, which arise as a result of autoimmune inflammation. The article summarizes systemic (fatigue, fever), cutaneous (rash, itching), gastrointestinal (diarrhea, colitis, hepatitis, pancreatic dysfunction), endocrinological (hypothyroidism, hypophysitis, adrenal insufficiency, diabetes mellitus), pulmonary (pneumonitis, pleuritis), rheumatological (arthralgia), neurological (headache, sensory and motor disorders), renal (acute interstitial nephritis, lupus-like nephritis, granulomatous nephritis, diffuse interstitial nephritis and minimal change disease), hematological (anemia, cytopenia), cardiovascular (myocarditis) and ocular (conjunctivitis, episcleritis, ceratitis, blepharitis and uveitis) imAE. Pathogenetic mechanisms and treatment approaches (in accordance with toxicity grade and clinical recommendations) are discussed. Early symptom recognition, patient education and timely intervention are crucial for imAE correction.
format	article
author	Marina A. Lyadova Vladimir K. Lyadov
author_facet	Marina A. Lyadova Vladimir K. Lyadov
author_sort	Marina A. Lyadova
title	Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
title_short	Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
title_full	Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
title_fullStr	Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
title_full_unstemmed	Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
title_sort	immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/3a154e511d494ed0b9aa3f44adddd121
work_keys_str_mv	AT marinaalyadova immunemediatedadverseeventsinimmunecheckpointinhibitorstherapyliteraturereview AT vladimirklyadov immunemediatedadverseeventsinimmunecheckpointinhibitorstherapyliteraturereview
_version_	1718406438187958272

Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review

Ejemplares similares